Loading clinical trials...
Loading clinical trials...
The purpose of this long term extension study is to assess safety, tolerability and immunogenicity of ACC-001 with QS-21 adjuvant in Japanese subjects with mild to moderate AD who were randomized in t...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
Collaborators
NCT07666113 · Alzheimer's Disease (AD)
NCT07214727 · Alzheimer's Disease
NCT06745583 · Mild, Moderate, or Severe Alzheimer's Disease
NCT07040904 · Mindfulness, Alzheimer's Disease Related Dementia
NCT05592678 · Alzheimer's Disease (AD), Dementia, and more
Meitetsu Hospital
Nagoya, Aichi-ken
Ibaraki Prefectural Central Hospital
Kasama, Ibaraki
Shonan Atsugi Hospital
Atsugi, Kanagawa
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions